登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603997 证券简称：继峰股份 公告编号：2025-042 转债代码：110801 转债简称：继峰定01 宁波继峰汽车零部件股份有限公司 关于2025年员工持股计划 非交易过户完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 宁波继峰汽车零部件股份有限公司（以下简称"公司"）于2025年4月9日和2025年4月28日分别召开了第 五届董事会第十七次会议及2024年年度股东大会，审议通过了《关于公司＜2025年员工持股计划（草 案）＞及其摘要的议案》《关于公司＜2025年员工持股计划管理办法＞的议案》等相关议案，具体内容 详见公司在2025年4月10日、2025年4月29日于上海证券交易所网站（http://www.sse.com.cn/）披露的相 关公告。 根据《关于上市公司实施员工持股计划试点的指导意见》《上海证券交易所上市公司自律监管指引第1 号一一规范运作》的要求，现将公司2025年员工持股计划实施进展情况公告如下： 根据参与对象实际认购和最终缴 ...

Core Viewpoint - The company has successfully completed the non-trading transfer of shares under its 2025 Employee Stock Ownership Plan (ESOP), which aims to enhance employee engagement and align their interests with the company's performance [1][6]. Group 1: Employee Stock Ownership Plan Details - The 2025 ESOP was approved during the company's board and shareholder meetings held on March 7, 2025, and March 27, 2025, respectively [1]. - The plan involves the transfer of 12,351,780 shares, representing 1.59% of the company's total share capital, from the company's repurchased shares [4][6]. - The total amount raised from employee contributions to the ESOP is approximately RMB 139.58 million, with 448 employees participating [5]. Group 2: Share Repurchase and Funding - The shares for the ESOP were sourced from the company's repurchased A-shares, with a total of 9,679,297 shares repurchased in 2022 and 4,584,553 shares in 2023 [2][3]. - The total amount spent on share repurchases was approximately RMB 199.99 million in 2022 and RMB 69.92 million in 2023 [2][3]. - As of the last transfer, the company had a total of 22,122,142 shares available for the ESOP, which is 2.85% of the total share capital [4]. Group 3: Plan Structure and Governance - The ESOP has a duration of 60 months, with shares unlocking in three phases based on performance metrics [6]. - The plan does not involve any financial assistance or guarantees from the company to the participants [5]. - Participants in the ESOP will voluntarily waive their voting rights associated with the shares held under the plan [7]. Group 4: Accounting Treatment - The expenses related to the ESOP will be amortized according to relevant accounting standards, impacting the company's net profit during the plan's duration [8]. - The plan is expected to positively influence employee motivation and operational efficiency, although the exact financial impact will be determined by annual audit reports [8].

德生科技（002908）公告，公司2025年员工持股计划非交易过户已完成，过户股份数量为174.56万股， 占公司目前总股本4.31亿股的0.40%，过户价格为4.43元/股。本次员工持股计划实际参与认购份额的员 工人数为61人，实际缴纳认购资金总额为773.3万元。公司已在中国证券登记结算有限责任公司深圳分 公司开立了本次员工持股计划专用证券账户，证券账户号码为8.99亿。此次回购股份已处理完成，实际 用途与回购股份方案中的拟定用途不存在差异。 ...

Core Viewpoint - Nanjing Novogene Bioinformatics Technology Co., Ltd. plans to repurchase its shares through centralized bidding, with a total repurchase amount ranging from RMB 5 million to RMB 10 million, aimed at implementing equity incentives or employee stock ownership plans [1][4][6]. Summary by Relevant Sections Repurchase Plan Details - The repurchase amount is set between RMB 5 million and RMB 10 million [1][4]. - The funding source for the repurchase will be the company's own funds [1][4]. - The maximum repurchase price is capped at RMB 30 per share, which does not exceed 150% of the average trading price over the last 30 trading days prior to the board's decision [1][4][6]. - The repurchase will be conducted through the Shanghai Stock Exchange's trading system [1][5]. - The duration for the repurchase is within 12 months from the board's approval date [1][4]. Purpose and Use of Repurchased Shares - The repurchased shares will be used for implementing equity incentives or employee stock ownership plans [1][4][8]. - If the company fails to implement these plans within three years after the repurchase, the unutilized shares will be canceled [1][4][12]. Shareholder and Management Plans - Major shareholders, including the actual controller and board members, have no plans to reduce their holdings in the next three to six months [2][10][11]. - The proposal for the repurchase was initiated by the actual controller and chairman, Mr. Cao Lin, based on confidence in the company's future development [12][13]. Financial Impact and Structure Changes - As of March 31, 2025, the company's total assets were RMB 5.266 billion, with net assets attributable to shareholders at RMB 3.901 billion [8]. - The repurchase amount, if at the upper limit of RMB 10 million, would represent approximately 0.02% of total assets and 0.26% of net assets [8]. - The repurchase is expected to have no significant impact on the company's operations, financial status, or future development [8]. Compliance and Authorization - The repurchase plan has been approved by more than two-thirds of the board members and does not require shareholder meeting approval [3][4]. - The management is authorized to handle all matters related to the repurchase, including adjustments to the plan as necessary [13][14].

Core Viewpoint - The legal opinion letter from Yuanwen (Shanghai) Law Firm confirms the legality and compliance of Suzhou Mingzhi Technology Co., Ltd.'s differentiated dividend distribution for the fiscal year 2024, ensuring it aligns with relevant laws and regulations [1][8]. Group 1: Differentiated Dividend Distribution - The differentiated dividend distribution is necessitated by the company's repurchased shares, which do not participate in profit distribution as per the relevant laws and regulations [4][5]. - The company plans to distribute a cash dividend of 4.50 yuan per 10 shares (including tax), excluding the 534,750 shares held in the repurchase account from this distribution [5][6]. - The total number of shares eligible for profit distribution is calculated to be 123,421,322 shares after excluding the repurchased shares from the total share capital of 123,956,072 shares [6][7]. Group 2: Legal Compliance and Verification - The law firm has conducted thorough verification of the legal compliance of the differentiated dividend distribution, ensuring no false records or misleading statements exist [2][3]. - The legal opinion letter serves as a necessary legal document for the company's differentiated dividend distribution and is subject to legal responsibility by the law firm [2][3]. - The law firm emphasizes that it only provides opinions on legal matters related to the differentiated dividend distribution and does not assess accounting or financial aspects [3][4].

中信证券股份有限公司 关于辽宁成大生物股份有限公司 以集中竞价交易方式回购公司股份的核查意见 中信证券股份有限公司（以下简称"保荐机构"或"中信证券"）作为辽宁 成大生物股份有限公司（以下简称"成大生物"或"公司"）首次公开发行股票 并在科创板上市的持续督导保荐机构，根据《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》《上市公司募集资金监管规则》《上海证券 交易所上市公司自律监管指引第 7 号——回购股份》等有关规定，对公司以集 中竞价交易方式回购股份的事项进行了核查，具体情况如下： 一、回购方案的审议及实施程序 金通过上海证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人 民币普通股（A股）股票。具体内容详见 公司在上海证券交易所网站 （www.sse.com.cn）披露的《辽宁成大生物股份有限公司关于公司董事长提议回 购公司股份的提示性公告》（公告编号：2025-032）。 以集中竞价交易方式回购公司股份方案的议案》。公司全体董事出席会议，表决 结果为9票同意、0票反对、0票弃权，经三分之二以上董事出席的董事会会议决 议通过。根据《上市公司股份回购规则》及《公司章程》之规定，本 ...

证券代码：603997 证券简称：继峰股份 公告编号：2025-043 转债代码：110801 转债简称：继峰定 01 宁波继峰汽车零部件股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 宁波继峰汽车零部件股份有限公司（以下简称"公司"）2025 年员工持股计 划第一次持有人会议于 2025 年 6 月 19 日以现场结合通讯表决方式召开。本次会 议由公司董事会秘书刘杰先生召集和主持，出席本次会议的持有人共 91 人，代表 会议审议通过了以下议案： 表决结果：同意 31,578,000 份，占出席持有人会议的持有人所持份额总数的 二、审议通过《关于选举 2025 年员工持股计划管理委员会委员的议案》 经审议表决，选举张畅、吴建东、刘大刚为公司 2025 年员工持股计划管理委 员会委员，任期为 2025 年员工持股计划的存续期。选举张畅为管理委员会主任， 任期为 2025 年员工持股计划的存续期。管理委员会委员与公司控股股东、实际控 制人、董事、监事、高级管理人员不存在一致行动关系。 表决结果：同意 31,578 ...

Core Viewpoint - The company faces significant challenges due to a decline in stock valuation, leading to employee dissatisfaction and potential legal disputes regarding the employee stock ownership plan [1][2][5]. Group 1: Employee Stock Ownership Plan - The employee stock ownership plan involved 794 participants contributing nearly 1.8 billion yuan for a 4.55% stake in the company, with an average investment of approximately 2.24 million yuan per participant [2][3]. - The plan aimed to bind core talent and was seen as a strategic move to enhance employee motivation and retention [3][4]. - As of 2025, employees are facing pressure to repay principal amounts after a five-year lock-in period, with some employees potentially losing their investments due to the company's declining performance [5][6]. Group 2: Company Performance - In 2024, the company's sales dropped to 374,900 units, a year-on-year decline of 21.19%, significantly below the annual target of 700,000 units [4]. - The first quarter of 2025 saw a further decline, with sales in May plummeting by 33.18% year-on-year, indicating a worsening trend [4][5]. - The company has struggled with product strategy failures and increased competition from rivals like BYD and Xpeng, leading to a saturated B-end market and challenges in expanding into the consumer market [4][6]. Group 3: IPO and Market Challenges - The company's IPO plans have been indefinitely postponed, with the CEO acknowledging that the current market conditions are not favorable for an IPO [5]. - The company has attempted to implement price reductions across its product line, but the market response has been minimal, indicating deeper issues with product acceptance [6]. - The overall market environment for electric vehicles is becoming increasingly challenging, with external factors such as potential tariffs on Chinese electric vehicles adding to the difficulties faced by the company [6].

一、持股计划相关情况 （一）第二期持股计划审议及披露情况 1、公司于2022年5月31日召开第七届董事会第十九次会议及2022年7月22日召开的2022年第二次临时股 东大会审议通过《TCL科技集团股份有限公司2021-2023年员工持股计划（第二期）（草案）》（以下 简称"第二期持股计划"）以及《TCL科技集团股份有限公司2021-2023年员工持股计划（第二期）管理 办法》。 登录新浪财经APP 搜索【信披】查看更多考评等级 TCL科技集团股份有限公司及董事会全体成员保证公告内容的真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 TCL科技集团股份有限公司（以下简称"公司"）于近日完成了2021－2023年员工持股计划（第二期）及 2021－2023年员工持股计划（第三期）已归属持有人的部分股票非交易过户手续。现将相关情况公告如 下： 2、2022年12月30日，公司发布《2021-2023年员工持股计划（第二期）非交易过户完成的公告》，第二 期持股计划通过非交易过户方式获得已回购库存股股数（即过户数量）合计为106,484,364股。 3、2023年5月31日，公司发布《关于2021-202 ...

Group 1 - The company held its third board meeting and supervisory board meeting on June 17, 2025, where it approved the use of its own foreign exchange funds to pay for the investment project and to replace it with raised funds [2][7][9] - The company successfully raised a total of RMB 182,032.60 million by issuing 14,470,000 shares at a price of RMB 125.80 per share, with a net amount of RMB 165,101.28 million after deducting issuance costs [2][43][44] - The company plans to use the raised funds for the "Anjisi Thailand Production Base Project" and has established a three-party supervision agreement for the management of the raised funds [3][4][43] Group 2 - The company will use its own foreign exchange funds to pay for part of the investment project during its implementation and will replace these with raised funds later, which is aimed at improving operational efficiency and reducing financial costs [5][6][7] - The company has approved the extension of the "Minimally Invasive Medical Device R&D Center Project" to December 31, 2026, due to the actual construction progress and strategic planning [4][54][55] - The supervisory board and the sponsor have confirmed that the use of foreign exchange funds and the extension of the investment project will not affect the normal implementation of the investment projects and will not harm the interests of shareholders [8][9][57] Group 3 - The company has established a detailed operational process for the use of its own foreign exchange funds and the subsequent replacement with raised funds, ensuring compliance with relevant regulations [6][8][9] - The company emphasizes the necessity and feasibility of the investment projects, highlighting the importance of technological innovation and talent attraction in maintaining competitive advantages in the medical device industry [46][50][51] - The company believes that the investment projects align with its strategic planning and will continue to monitor conditions for timely adjustments [52][53]